Fetuin-A is associated with disease severity and exacerbation frequency in patients with COPD

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 10, Issue 1, 2013, Pages 28-34

  Minas, Markos ^a   Mystridou, Parthena ^a   Georgoulias, Panagiotis ^a   Pournaras, Spyros ^a   Kostikas, Konstantinos ^a   Gourgoulianis, Konstantinos I ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

Biomarker; COPD; Exacerbation; Fetuin A; Systemic inflammation

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FETUIN A;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; EXERCISE; FEMALE; FOLLOW UP; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTPATIENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; QUALITY OF LIFE; REPRODUCIBILITY; SMOKING; STATISTICAL SIGNIFICANCE; TERTIARY HEALTH CARE; UNIVERSITY HOSPITAL;

EID: 84874071214     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2012.727922     Document Type: Article

References (37)

1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176(6):532-555.
2. Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. Chest 2011; 139(1):165-173.
3. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 2007; 370(9589):797-799.
4. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: A systematic review and a meta-Analysis. Thorax 2004; 59(7):574-580.
5. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21(2):347-360.
6. Garcia-Rio F, Miravitlles M, Soriano JB, Munoz L, Duran-Tauleria E, Sanchez G, Sobradillo V, Ancochea J. Systemic inflammation in chronic obstructive pulmonary disease: A population-based study. Respir Res 2010; 11:63.
7. Sin DD, Man SF. Systemic inflammation and mortality in chronic obstructive pulmonary disease. Can J Physiol Pharmacol 2007; 85(1):141-147.
8. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175(3):250-255.
9. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57(10):847-852.
10. Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173(1):71-78.
11. Markoulaki D, Kostikas K, Papatheodorou G, Koutsokera A, Alchanatis M, Bakakos P, Gourgoulianis KI, Roussos C, Koulouris NG, Loukides S. Hemoglobin, erythropoietin and systemic inflammation in exacerbations of chronic obstructive pulmonary disease. Eur J Intern Med 2011; 22(1):103-107.
12. Koutsokera A, Kiropoulos TS, Nikoulis DJ, Daniil ZD, Tsolaki V, Tanou K, Papaioannou AI, Germenis A, Gourgoulianis KI, Kostikas K. Clinical, functional and biochemical changes during recovery from COPD exacerbations. Respir Med 2009; 103(6):919-926.
13. Groenewegen KH, Postma DS, Hop WC, Wielders PL, Schlosser NJ, Wouters EF. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 2008; 133(2):350-357.
14. Brown WM, Saunders NR, Mollgard K, Dziegielewska KM. Fetuin-An old friend revisited. Bioessays 1992; 14(11):749-755.
15. Lim P, Collet JP, Moutereau S, Guigui N, Mitchell-Heggs L, Loric S, Bernard M, Benhamed S, Montalescot G, Rande JL, Gueret P. Fetuin-A is an independent predictor of death after ST-elevation myocardial infarction. Clin Chem 2007; 53(10):1835-1840.
16. Bilgir O, Kebapcilar L, Bilgir F, Bozkaya G, Yildiz Y, Pinar P, Tastan A. Decreased serum fetuin-A levels are associated with coronary artery diseases. Intern Med 2010; 49(13):1281-1285.
17. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan G, Knobil K, Lomas DA, MacNee W, Silverman EK, Tal-Singer R. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J: OffJ Eur Soc Clin Respir Physiol 2008; 31(4):869-873.
18. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988; 93(3):580-586.
19. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A selfcomplete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992 Jun; 145(6):1321-1327.
20. American Thoracic Society. Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med 1995; 152(3):1107-1136.
21. ATS Statement. Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166(1):111-117.
22. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350(10):1005-1012.
23. Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC, Jr., Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109(3):433-438.
24. Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, Joost HG, Haring HU, Boeing H, Fritsche A. Plasma fetuin-A levels and the risk of myocardial infarction and ischemic stroke. Circulation 2008; 118(24):2555-2562.
25. Brix JM, Stingl H, Hollerl F, Schernthaner GH, Kopp HP, Schernthaner G. Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. J Clin Endocrinol Metab 2010; 95(11):4877-4881.
26. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of comorbidities. Eur Respir J 2006 Dec; 28(6):1245-1257.
27. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32(4):962-969.
28. Watz H, Waschki B, Kirsten A, Muller KC, Kretschmar G, Meyer T, Holz O, Magnussen H. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 2009; 136(4):1039-1046.
29. Bolton CE, Evans M, Ionescu AA, Edwards SM, Morris RH, Dunseath G, Luzio SD, Owens DR, Shale DJ. Insulin resistance and inflammation-A further systemic complication of COPD. COPD 2007; 4(2):121-126.
30. Minas M, Kostikas K, Papaioannou AI, Mystridou P, Karetsi E, Georgoulias P, Liakos N, Pournaras S, Gourgoulianis KI. The association of metabolic syndrome with adipose tissue hormones and insulin resistance in patients with COPD without comorbidities COPD 2011; 8(6):414-420.
31. Garcia-Aymerich J, Gomez FP, Benet M, Farrero E, Basagana X, Gayete A, Pare C, Freixa X, Ferrer J, Ferrer A, Roca J, Galdiz JB, Sauleda J, Monso E, Gea J, Barbera JA, Agusti A, Anto JM. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax 2011; 66(5):430-7.
32. de Torres JP, Pinto-Plata V, Casanova C, Mullerova H, Cordoba-Lanus E, Muros de Fuentes M, Aguirre-Jaime A, Celli BR. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008; 133(6):1336-1343.
33. Boschetto P, Quintavalle S, Zeni E, Leprotti S, Potena A, Ballerin L, Papi A, Palladini G, Luisetti M, Annovazzi L, Iadarola P, De Rosa E, Fabbri LM, Mapp CE. Association between markers of emphysema and more severe chronic obstructive pulmonary disease. Thorax 2006; 61(12):1037-1042.
34. Ogawa E, Nakano Y, Ohara T, Muro S, Hirai T, Sato S, Sakai H, Tsukino M, Kinose D, Nishioka M, Niimi A, Chin K, Pare PD, Mishima M. Body mass index in male patients with COPD: correlation with low attenuation areas on CT. Thorax 2009; 64(1):20-25.
35. Han MK, Kazerooni EA, Lynch DA, Liu LX, Murray S, Curtis JL, Criner GJ, Kim V, Bowler RP, Hanania NA, Anzueto AR, Make BJ, Hokanson JE, Crapo JD, Silverman EK, Martinez FJ, Washko GR. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: Associated radiologic phenotypes. Radiology 2011; 261(1):274-282.
36. Koutsokera A, Stolz D, Loukides S, Kostikas K. Systemic bomarkers in exacerbations of COPD: The evolving clinical challenge. Chest 2011; 141(2):396-405.
37. Perera WR, Hurst JR, Wilkinson TM, Sapsford RJ, Mullerova H, Donaldson GC, Wedzicha JA. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007; 29(3):527-534.